Interested in Cartistem Clinical Trials? On this page, we have collected links for you, where you will receive the most necessary information about Cartistem Clinical Trials.
https://clinicaltrials.gov/ct2/show/NCT04310215
Mar 17, 2020 · The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM® (allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.
https://clinicaltrials.gov/ct2/show/NCT01733186
Nov 26, 2012 · CARTISTEM®, a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, is intended to be used as a single-dose cellular therapeutic agent for cartilage regeneration in human subjects with cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
https://clinicaltrials.gov/ct2/show/NCT01626677
Jun 25, 2012 · Brief Summary: This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture.
http://www.medi-post.com/cartistem/
CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma. *ICRS grade : A diagnostic criteria used for grading the severity of cartilage defect.
https://ichgcp.net/clinical-trials-registry/NCT01626677
Brief Summary This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture.
http://www.medi-post.com/stem-cell-therapeutic/2020/09/36660/
MEDIPOST, a leading stem cell biotechnology company, today announced the initiation of a phase 2 clinical trial of CARTISTEM ®, an allogeneic stem cell therapy product for knee osteoarthritis, in Japan.
https://centerwatch.com/clinical-trials/listings/condition/751/cartilage-injuries/
The trial evaluates the clinical efficacy and safety of decalcification bone scaffold for cartilage lesions of the knee. Half of participants will receive decalcification bone scaffold combined with microfracture, while the other will only receive microfracture as a control group. 0 views 25 Jan, 2021
https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
There are several types of ACT (see the box below, titled "ACT: TILs, TCRs, and CARs"), but, thus far, the one that has advanced the furthest in clinical development is called CAR T-cell therapy. Until recently, the use of CAR T-cell therapy has been restricted to small clinical trials, largely in patients with advanced blood cancers.
http://stemcellsfreak.com/2013/01/Cartistem-clinical-trial.html
Jan 25, 2013 · Goal of the clinical trial is to test the safety and efficiency of the Cartistem product in patients with localised cartilage defects. As mentioned before, 12 patients will be enrolled. At first, 6 patients with cartilage defects measuring 2 to 5 centimetres will be treated, and later 6 more with bigger lesions will be enrolled.
https://clinicaltrials.gov/
Explore 369,687 research studies in all 50 states and in 219 countries. See listed clinical studies related to the coronavirus disease (COVID-19) ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.
We hope you have found all the information you need about Cartistem Clinical Trials through the links above.
